TN-NASHVILLE-SOCCER-CLUB
2.3.2023 15:01:39 CET | Business Wire | Press release
As Nashville Soccer Club enters its fourth season in Major League Soccer, and second at GEODIS Park, principal owner John Ingram announced today that leading scorer in Nashville Predator history Filip Forsberg and two-time MVP and NBA Champion Giannis Antetokounmpo have joined the team’s ownership group.
Antetokounmpo is joined in ownership by his brothers Thanasis, Kostas and Alex as well – all of whom play professional basketball worldwide. Thanasis joined Giannis in winning the NBA Championship with the Milwaukee Bucks in 2021, and Kostas won one with the Los Angeles Lakers in 2020.
The announcement of the new owners continues the strong momentum built by Nashville SC in the lead-up to the 2023 season, highlighted by its 'Man in Black’ jersey collaboration with the Estate of Johnny Cash. That momentum continued with a 2-0 victory over New York City FC in front of 28,051 fans at GEODIS Park this past Saturday.
Forsberg and Antetokounmpo join a robust and diverse ownership group whose most recent additions include Reese Witherspoon, her husband Jim Toth and Derrick Henry.
“Nashville is the best sports city in the country, and I am extremely blessed to now be involved with two of our pro teams,” said Forsberg. “Our city is one big family and fanbase, and we support each other on and off the field. Nashville SC has been such a great addition to our sports culture, and joining the ownership group was an opportunity I wasn’t going to pass up. I grew up a Liverpool FC fan in Sweden, and after today I am happy to add a second set of colors to cheer for!”
“My father was a professional soccer player, and it was the first sport I fell in love with in Greece,” said Antetokounmpo. “I’ve always had the dream of owning a soccer team. When my brothers and I explored Nashville SC, we knew it was a team and a city that we wanted to get involved with. I couldn’t be more excited to join the Boys in Gold, and can’t wait to come to a match at GEODIS Park soon!”
“Soccer is a global sport, and our newest owners once again reinforce our club’s commitment to being a global team,” said Ingram. “Filip and Giannis are not just amazing athletes – they are ambassadors for their respective sports, role models for millions and advocates in their hometowns and worldwide. We share a common belief that our teams not only play to the highest standards, but also lift up their communities and help those who need it most.”
Nashville SC takes on the road to face the New York Red Bulls at 6:30 p.m. CT on Saturday, March 4. Fans ns can follow the action on the MLS Season Pass on the Apple TV app and the club on its digital and social channels on Instagram, Facebook, TikTok, Twitter and Spotify.
MEDIA RESOURCES:
- Nashville SC Media Center with news, b-roll from training, match notes, other video and photo resources
- Media looking to follow NSC on social media can find the club on TikTok, Twitter and Instagram with the handle @NashvilleSC. For Facebook and YouTube please use “Nashville Soccer Club”
- The official club hashtag when referring to Nashville SC on social media is #EveryoneN
FOR MORE INFORMATION, CONTACT: Zach Hunt, zach@tsgnashville.com, 615.321.3110.
About Nashville SC
Nashville SC joined Major League Soccer on Feb. 29, 2020 in front of the largest attendance ever recorded for a soccer match in the State of Tennessee. In its inaugural MLS season, Nashville SC defeated expectations by becoming the second MLS expansion side to win and advance to the Conference Semifinals in the 2020 Audi MLS Cup Playoffs. Nashville SC returned to the 2021 Audi MLS Cup Playoffs in its sophomore season after becoming just the seventh team in MLS history to go unbeaten at home in a season. Nashville SC inaugurated GEODIS Park, the largest soccer-specific stadium in the United States and Canada, in front of a 30,109-sellout crowd on May 1, 2022. For more information, visit NashvilleSC.com and follow the club at @NashvilleSC on Instagram, Facebook, Twitter and Spotify.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005537/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom